PLOS One corrects duplicated figure panel in cisplatin-vorinostat nanoparticle study

PLOS One has issued a correction to the paper on niosomal nanoparticles loaded with cisplatin and vorinostat for cancer therapy after an image error appeared in the published record. The notice states that Fig 4C in the original article was incorrect and overlapped with Fig 3D from a separate 2025 paper by different authors and publishers. A corrected Fig 4 now accompanies the notice, along with the image data underlying the replaced panel in S1 File.

The correction does not alter the quantified results reported for Fig 4. That statement is clinically important because the figure in question sits inside the characterization package for a drug-delivery platform, where image integrity supports confidence in the physical properties of the formulation rather than direct patient outcomes.

What the corrected figure adds to the formulation record

The corrected figure concerns the physical characterization and stability of the NIO-CIS-VOR formulation. In the captioned material, panel A shows a narrow size distribution centered at about 150 nm, a readout that is consistent with a relatively uniform nanoparticle population. Panel B shows zeta potential values near −10 mV, a surface-charge profile that can influence dispersion behavior and colloidal stability. Panel C contains the transmission electron microscopy image that required correction, while panel D shows stability at 4°C over 60 days, with hydrodynamic diameter and zeta potential remaining consistent over time.

In drug delivery science, these parameters are not cosmetic. Particle size affects circulation behavior, tissue penetration, and cellular uptake; surface charge influences aggregation and interaction with biological membranes; and storage stability determines whether a formulation can survive long enough to be handled, shipped, and studied reproducibly. A duplicated micrograph inside this framework does not necessarily invalidate the broader chemistry or formulation logic, but it does demand a clean correction when the visual evidence no longer matches the published record.

The corrected panel also clarifies a licensing issue. The overlapping material came from a 2025 Elsevier paper on co-encapsulation of coumarin and Q10 into solid lipid nanoparticles for wound healing, which is not available under the same CC BY license governing the PLOS One article. The correction therefore serves two functions at once: restoring the integrity of the figure set and removing reused material that could not remain in the original open-access publication as printed.

Why this matters for cisplatin and vorinostat delivery research

The parent article focuses on the combination of cisplatin and vorinostat inside a niosomal carrier, a strategy aimed at improving how two anticancer agents are delivered together. Cisplatin remains a backbone cytotoxic drug in many tumors, while vorinostat is an epigenetic modulator with potential to alter tumor cell response and sensitize malignant tissue to treatment. Packaging both agents in a nanoparticle system is meant to improve co-delivery, stabilize the compounds, and potentially alter release behavior in a way that free-drug administration cannot easily achieve.

For that reason, every figure in a formulation paper carries weight. A TEM image helps confirm the morphology claimed in the text, and when a panel is reused from an unrelated publication, the concern is not only about copyright compliance but about whether the visual record truly belongs to the formulation being described. The correction asserts that the quantified findings were unaffected, which means the size, charge, and stability data remain the operative points for readers evaluating the platform.

This is a reminder that nanomedicine papers live or die on reproducibility. Small deviations in particle architecture can alter distribution, release, and stability, and those properties become even more consequential when a carrier is intended to deliver a platinum compound alongside an HDAC inhibitor-like agent such as vorinostat. A clean dataset matters because downstream preclinical work often uses these characterization figures as the foundation for dosing, release testing, and biological assays.

One duplicated panel can ripple far beyond a single image. It can complicate how future investigators judge comparability, especially when they are deciding whether to build on the same nanoparticle recipe or to cite the platform as evidence of formulation robustness.

The correction does not reset the science, but it does reset the record

The notice does not announce a change in the formulation’s measured performance, and it does not describe a revision to the chemistry, loading process, or stability outcome. Instead, it corrects the published visual evidence and links readers to the supporting image data. For readers of cancer nanotechnology research, that distinction is straightforward: the scientific premise may remain intact, but the publication record now reflects the correct figure and the correct provenance.

The notice is also a useful example of how post-publication correction functions in practice. In complex biomaterials research, image overlap can arise from assembly errors, file handling mistakes, or unintended reuse during manuscript preparation. Whatever the mechanism, the correction restores transparency by identifying the problem panel, replacing it, and specifying the unaffected quantitative findings.

For clinicians and translational researchers watching nanocarrier development, the practical takeaway is limited but real. The formulation’s reported characterization remains in place, the stability data remain in place, and the corrected image now aligns with the article’s claims. What the notice leaves unresolved is not the cancer application itself, but the extent to which the broader platform will ultimately translate beyond preclinical characterization into therapeutic testing with clinical relevance.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by PLOS Medicine.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA